文献速递血液淋巴病理乳腺病理泌尿与男性生殖病理

靶向蛋白降解在癌症治疗与研究中的新兴作用

The emerging role of targeted protein degradation to treat and study cancer.
PubMed 文献 · J Pathol · 2024-06-17

本文综述靶向蛋白降解策略在癌症治疗与研究中的进展,重点讨论沙利度胺类似物通过CRBN介导蛋白降解的机制,以及PROTACs等异双功能分子在临床试验中的早期成功,并探讨其转化优势与挑战。

要点

  • 沙利度胺类似物通过CRBN介导蛋白降解,最初用于多发性骨髓瘤。
  • PROTACs等靶向蛋白降解分子可靶向转录因子等传统难成药蛋白。
  • PROTACs已在临床试验中靶向雌激素受体和雄激素受体。

核心结论

  • 靶向蛋白降解拓展了可成药蛋白范围,并在多发性骨髓瘤之外显示应用潜力。
  • PROTACs已进入临床试验,早期在乳腺癌和前列腺癌中靶向雌激素受体和雄激素受体。

主要发现

  • 沙利度胺类似物通过CRBN介导蛋白降解,其新靶点鉴定加速了药物开发。
  • 靶向蛋白降解应用扩展至非霍奇金淋巴瘤、骨髓增生异常综合征和急性白血病。
  • 转录因子是靶向蛋白降解最早描述的一类经典靶点。
  • 分子胶和PROTACs是靶向蛋白降解剂的代表类型。

临床怎么用

  • 靶向蛋白降解可用于治疗和研究癌症,尤其针对传统方法难以成药的转录因子和融合蛋白。

局限性

  • 靶向蛋白降解在转化开发中仍存在潜在优势与挑战待进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The evolution of cancer treatment has provided increasingly targeted strategies both in the upfront and relapsed disease settings. Small-molecule inhibitors and immunotherapy have risen to prominence with chimeric antigen receptor T-cells, checkpoint inhibitors, kinase inhibitors, and monoclonal antibody therapies being deployed across a range of solid organ and haematological malignancies. However, novel approaches are required to target transcription factors and oncogenic fusion proteins that are central to cancer biology and have generally eluded successful drug development. Thalidomide analogues causing protein degradation have been a cornerstone of treatment in multiple myeloma, but a lack of in-depth mechanistic understanding initially limited progress in the field. When the protein cereblon (CRBN) was found to mediate thalidomide analogues' action and CRBN's neo-targets were identified, existing and novel drug development accelerated, with applications outside multiple myeloma, including non-Hodgkin's lymphoma, myelodysplastic syndrome, and acute leukaemias. Critically, transcription factors were the first canonical targets described. In addition to broadening the application of protein-degrading drugs, resistance mechanisms are being overcome and targeted protein degradation is widening the scope of druggable proteins against which existing approaches have been ineffective. Examples of targeted protein degraders include molecular glues and proteolysis targeting chimeras (PROTACs): heterobifunctional molecules that bind to proteins of interest and cause proximity-induced ubiquitination and proteasomal degradation via a linked E3 ligase. Twenty years since their inception, PROTACs have begun progressing through clinical trials, with early success in targeting the oestrogen receptor and androgen receptor in breast and prostate cancer respectively. This review explores important developments in targeted protein degradation to both treat and study cancer. It also considers the potential advantages and challenges in the translational aspects of developing new treatments. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Brodermann MH, Henderson EK, Sellar RS, et al. The emerging role of targeted protein degradation to treat and study cancer. J Pathol. 2024. PMID: 38886898. doi:10.1002/path.6301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。